Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

Inclusion Criteria: Relapsed/advanced thymoma B3 and thymic carcinoma not amenable to curative-intent radical treatment; At least one previous line of platinum-based chemotherapy for advanced disease * Patients treated with neo-adjuvant or adjuvant platinum based chemotherapy combined with radical surgical or as part of radical chemoradiotherapy are eligible if chemotherapy was completed less than 6 months before enrollment; * Radiological progression documented per RECIST 1.1 during or after completion of previous line therapy; * Presence of measurable disease according to RECIST 1.1. * Disease status must be documented by full chest and upper abdomen (including adrenal glands) CT and/or MRI within 28 days of study enrollment. If clinically indicated, brain imaging must be performed * At least 18 years; * WHO Performance Status (PS) 0-2 Note: for the cohort of patient that will be treated with nivolumab and ipilimumab: PS 0-1 * Availability of FFPE tumor tissue (a tumour block or 10 unstained slides), notably for PD-L1 Immunohistochemistry (IHC) expression assessment. Archival material is allowed. Patients will be eligible to participate regardless of the level of PD-L1 expression, however tissue must be considered adequate (assessed by a local pathologist) for characterization of PD-L1 status as per procedure manual; * Adequate hematological function: * white blood count ≥ 2 × 109/L; * haemoglobin \>9 g/dL; * platelet count \>100 × 109/L; * Adequate liver function: * Tot…